Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What The Smart Money Thinks Of Barclays’ Top Healthcare Picks: Alexion Pharmaceuticals, Inc. (ALXN), Baxter International Inc (BAX), & Valeant Pharmaceuticals Intl Inc (VRX)

Page 1 of 2

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Baxter International Inc (NYSE:BAX), and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) are among the top healthcare stock picks of Barclays PLC (ADR) (NYSE:BCS) in its Americas Top Picks List released yesterday. We decided to look at these stock investments and the respective hedge fund sentiment on each of them to see whether the smart money agrees with Barclays’ assessment, potentially making these very compelling picks as we prepare to head into the second half of 2015.

Best Paying Medical Jobs with Least Education

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 145% and beating the market by more than 85 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise rather than large-cap stocks.

What makes Alexion Pharmaceuticals an interesting stock is the fact it has replaced Gilead Sciences, Inc. (NASDAQ:GILD) to become the top stock in Barclays PLC (ADR) (NYSE:BCS)’s list. The analyst firm expects further upside from the current stock price of Alexion because of its steadily growing product Soliris, which is used in the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH), and other pipeline medications including Strensiq and Kanuma. Both Strensiq and Kanuma have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which is a part of the European Medicines Agency (EMA). Strensiq is used for the treatment of bone manifestations originating from pediatric-onset hypophosphatasia (HPP), and Kanuma is used against lysosomal acid lipase deficiency (LAL-d). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) completed the acquisition of Synageva BioPharma Corp. (NASDAQ:GEVA) earlier last week, with Synageva set to work as a directly-owned subsidiary of Alexion Pharmaceuticals. It seems as if the hedge fund managers tracked at Insider Monkey were following the stock of Alexion Pharmaceuticals very closely and liked what they saw, as the company had received net investments of $1.32 billion from 48 hedge fund managers on March 31 against net investments of $1.10 billion from 44 hedge fund investors three months earlier. Ken Griffin’s Citadel Investment Group holds the largest position in Alexion among hedge funds tracked at Insider Monkey with a current position of 1.14 million shares valued at $197.88 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!